Researchers identify promising biomarkers and new therapeutic targets for kidney cancer
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up ...
Cancer
May 31, 2012 |
not rated yet |
0
Marked for destruction: Newly developed compound triggers cancer cell death
The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis. Cells are pressured toward apoptosis by expression of pro-apoptotic ...
Cancer
May 24, 2012 |
5 / 5 (1) |
0
Whole genome sequencing of rare olfactory neuroblastoma
The Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have conducted whole genome sequencing (WGS) of a rare nasal tract cancer called olfactory neuroblastoma ...
Genetics
May 23, 2012 |
not rated yet |
0
|
Dabrafenib shrinks melanoma brain metastases in phase I clinical trial
An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of ...
Cancer
May 17, 2012 |
not rated yet |
0
|
Want to avoid ED following prostate cancer surgery? Find an experienced, gentle surgeon
Prostate cancer is the most commonly diagnosed non-skin cancer in the U.S., and radical prostatectomy, the surgical removal of the prostate gland, remains the most popular therapeutic option, accounting for ...
Surgery
May 16, 2012 |
not rated yet |
0
|
Early biomarker for pancreatic cancer identified
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently ...
Cancer
May 15, 2012 |
5 / 5 (3) |
1
|
Drug kills cancer cells by restoring faulty tumor suppressor
A new study describes a compound that selectively kills cancer cells by restoring the structure and function of one of the most commonly mutated proteins in human cancer, the "tumor suppressor" p53. The research, published ...
Cancer
May 14, 2012 |
5 / 5 (1) |
0
Advanced pancreatic tumors depend on continued oncogene activity
Researchers at Dana-Farber Cancer Institute have shown that advanced pancreatic cancers in mice can't survive without continued expression of a mutant oncogene that "rewires" key metabolic pathways to fuel the cancer cells.
Cancer
Apr 26, 2012 |
not rated yet |
0
|
Mutant Kras drives pancreatic cancer maintenance via metabolic pathways
A genetic mutation that drives the initiation of pancreatic cancer also manipulates metabolic pathways to support tumor growth and progression, scientists report in the journal Cell.
Cancer
Apr 26, 2012 |
not rated yet |
0
|
New biomarker may predict prognosis for patients with chronic lymphocytic leukemia
Researchers at the University of California-San Diego School of Medicine have shown that G protein-coupled receptor expression may predict the prognosis of patients with chronic lymphocytic leukemia. Their findings may identify ...
Cancer
Apr 24, 2012 |
5 / 5 (1) |
0
Therapy exploits 'addiction' of leukemia cells
A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online ...
Cancer
Apr 16, 2012 |
not rated yet |
0
Target set on cancer gene MCL1
A research team pursuing one of the most commonly altered genes in cancer has laid a critical foundation for understanding this gene that could point the way toward developing drugs against it. A recent study of cancer genetics ...
Cancer
Apr 16, 2012 |
5 / 5 (2) |
0
|
Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have shown that breast cancer cells that metastasize to the lung express a higher level of the protein peroxiredoxin 2 (PRDX2). The study suggests that ...
Cancer
Apr 10, 2012 |
5 / 5 (1) |
0
BIND presents late-breaker clinical data at AACR on BIND-014's promising antitumor effects
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, ...
Cancer
Apr 04, 2012 |
not rated yet |
0
KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical ...
Cancer
Apr 04, 2012 |
not rated yet |
0
